“ADA 2026 GLP-1 Pipeline: Retatrutide, CagriSema, Orforglipron The Next Wave of Incretin Therapies Unveiled in New Orleans”. Diabzen, vol. 4, no. 23, July 2026, pp. 46-47, https://thediabzen.com/index.php/d/article/view/66.